# Adjuvant PARP Inhibitors for High-Risk Early-Stage HER2-Negative Breast Cancer: A Study Guide This study guide provides a comprehensive overview of the 2021 ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update. It focuses on the use of adjuvant PARP inhibitors in patients with germline BRCA mutations and high-risk, early-stage HER2-negative breast cancer. --- ## Key Concepts and Clinical Findings ### The Shift in Clinical Recommendations The 2020 ASCO-ASTRO-SSO guideline previously stated that there was insufficient data to recommend PARP inhibitors for patients with nonmetastatic breast cancer. However, the emergence of the OlympiA phase III trial data in June 2021 led to a rapid update, establishing a new standard of care for specific high-risk populations. ### The OlympiA Phase III Trial The OlympiA trial was a double-blind, randomized trial evaluating the efficacy of olaparib (a PARP inhibitor) as an adjuvant therapy. * **Participants:** Patients with early-stage, HER2-negative breast cancer, high risk of recurrence, and germline BRCA1 or BRCA2 pathogenic/likely pathogenic variants. * **Protocol:** One year of olaparib following local treatment and (neo)adjuvant chemotherapy (typically anthracycline- and taxane-based). * **Primary Outcomes (at 2.5-year median follow-up):** * **Invasive Disease-Free Survival (3-year):** 85.9% (olaparib) vs. 77.1% (placebo). * **Distant Disease-Free Survival (3-year):** 87.5% (olaparib) vs. 80.4% (placebo). * **Overall Survival:** While the estimated overall survival was higher in the olaparib group, the difference was not statistically significant at the time of the interim analysis. ### Safety and Adverse Events Olaparib was generally well-tolerated, with manageable safety profiles and no significant impact on global quality of life. * **Anemia:** This was the primary grade 3 or higher adverse event, occurring in 8.7% of the olaparib group versus 0.3% of the placebo group. * **Transfusions:** 5.8% of olaparib patients required at least one blood transfusion. * **Secondary Malignancies:** Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) were not more frequent in the olaparib arm at the interim analysis, though long-term follow-up is required. --- ## Summary of Updated Recommendations (2021) The current recommendation states that one year of adjuvant olaparib should be offered to patients with early-stage, HER2-negative breast cancer, high risk of recurrence, and germline BRCA1/2 mutations after completing chemotherapy and local treatment. Eligibility depends on the type of cancer and the treatment sequence: | Patient Category | Treatment Sequence | Criteria for Adjuvant Olaparib | | :--- | :--- | :--- | | **Triple-Negative (TNBC)** | Surgery First | Tumor size > 2 cm or any involved axillary nodes. | | **Hormone Receptor-Positive (HR+)** | Surgery First | At least four involved axillary lymph nodes. | | **Triple-Negative (TNBC)** | Neoadjuvant Chemotherapy First | Any residual invasive cancer in the surgical specimen. | | **Hormone Receptor-Positive (HR+)** | Neoadjuvant Chemotherapy First | Residual disease and a CPS+EG score of $\ge$ 3. | --- ## The CPS+EG Scoring System The CPS+EG score (Clinical stage, Pathologic stage, ER status, and Nuclear Grade) is used to determine eligibility for HR+ patients who have received neoadjuvant chemotherapy. | Feature | Category (AJCC Staging) | Points | | :--- | :--- | :--- | | **Clinical Stage** | I or IIA | 0 | | | IIB or IIIA | 1 | | | IIIB or IIIC | 2 | | **Pathologic Stage** | 0 or I | 0 | | | IIA, IIB, IIIA, or IIIB | 1 | | | IIIC | 2 | | **Receptor Status** | ER-negative | 1 | | **Nuclear Grade** | Grade 3 | 1 | *Note: If nuclear grade cannot be determined, regular histologic grade is used. A Nottingham overall grade of 3 is required to score 1 point.* --- ## Short-Answer Practice Questions 1. **What specific genetic markers must be present for a patient to be considered for adjuvant olaparib under these guidelines?** * *Answer:* Germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants. 2. **What was the primary clinical signal that triggered the rapid update of the 2020 ASCO guideline?** * *Answer:* A significant improvement in invasive and distant disease-free survival reported in the OlympiA phase III trial. 3. **For a patient with triple-negative breast cancer (TNBC) who undergoes surgery first, what are the two clinical criteria that would qualify them for olaparib?** * *Answer:* A tumor size greater than 2 cm or any involved axillary nodes. 4. **Which adverse event was reported at a Grade 3 level in more than 5% of patients in the OlympiA trial?** * *Answer:* Anemia (8.7%). 5. **Why can the OlympiA trial not inform the relative efficacy of olaparib compared to capecitabine?** * *Answer:* Because post-neoadjuvant capecitabine was not the standard of care when the trial was designed and was not permitted during the study. --- ## Essay Prompts for Deeper Exploration 1. **The Evolution of Evidence-Based Care:** Discuss the transition from the 2020 ASCO recommendation regarding PARP inhibitors to the 2021 update. Explain how the OlympiA trial results specifically addressed the "insufficient data" noted in the previous guideline and how this illustrates the "Rapid Recommendation Update" process. 2. **Risk Stratification in Adjuvant Therapy:** Compare and contrast the eligibility requirements for adjuvant olaparib between Triple-Negative Breast Cancer (TNBC) and Hormone Receptor-Positive (HR+) patients. Why might the criteria be more stringent (e.g., requiring a CPS+EG score or a higher number of nodes) for HR+ patients? 3. **Safety and Long-Term Monitoring:** While the safety profile of olaparib was deemed "manageable" in the interim analysis, the guideline suggests further follow-up is necessary for specific conditions. Identify these conditions and explain why PARP inhibitors require long-term surveillance regarding hematologic health. --- ## Glossary of Important Terms * **Adjuvant Therapy:** Treatment given after the primary treatment (such as surgery) to lower the risk of the cancer returning. * **CPS+EG Score:** A clinical-pathologic scoring system that incorporates Clinical stage, Pathologic stage, Estrogen receptor (ER) status, and nuclear Grade to assess risk in HR+ breast cancer. * **Distant Disease-Free Survival (DDFS):** The length of time after primary treatment for a cancer ends that the patient remains free of cancer spreading to distant parts of the body. * **Germline BRCA Mutation:** An inherited pathogenic or likely pathogenic variant in the BRCA1 or BRCA2 genes that increases the risk of developing breast and other cancers. * **HER2-Negative:** Breast cancer cells that do not have high levels of the HER2 protein, a factor used to determine specific treatment pathways. * **Invasive Disease-Free Survival (IDFS):** The length of time after primary treatment that a patient survives without the recurrence of invasive cancer. * **Neoadjuvant Chemotherapy:** Chemotherapy administered before the primary surgical treatment, often intended to shrink a tumor. * **PARP Inhibitor:** A type of drug (such as olaparib) that blocks poly(ADP-ribose) polymerase, an enzyme used by cells to repair DNA damage. In cells with BRCA mutations, blocking this enzyme can lead to cell death. * **Triple-Negative Breast Cancer (TNBC):** A type of breast cancer that tests negative for estrogen receptors, progesterone receptors, and HER2 protein.